Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial
The COSMID (Comparison of Surgery and Medicine on the Impact of Diverticulitis) trial is a pragmatic, patient-level randomized superiority trial of elective colectomy vs. best medical management for patients with quality of life (QoL) limiting diverticular disease. A parallel observational cohort will include those who are disinclined to have their treatment choice randomized, but are willing to contribute information about their outcomes. The goal of the COSMID trial is to answer the question: For patients with QoL-limiting diverticular disease, is elective colectomy more effective than best medical management? The hypothesis being tested in the COSMID trial is that patient-reported outcomes (PROs) among patients in the surgery arm will be superior to those in the best medical management arm.
• Adults ≥18 years
• At least one episode of diverticulitis confirmed by CT scan and a colonoscopy (completed or scheduled) to rule out or screen for other colon pathology in accordance with colorectal cancer screening guidelines
• Persistent signs, symptoms, or concerns related to diverticulitis after recovery from an episode of left-sided diverticulitis
• Self-reported QoL limitation (assessed with 12 questions modified from the Diverticulitis Quality of Life \[DV-QOL\] instrument).